Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Xgeva’

Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011

By on September 23, 2011

Radium-223 (Alpharadin) will be “Practice Changing” is how Michael Baumann, President of the European CanCer Organisation (ECCO) and Jean-Charles Soria, Co-Scientific chair of the 2011 Stockholm Multidisciplinary Cancer Congress described the prostate cancer clinical trial data to be presented in the Presidential (plenary) session on Saturday September 24, 2011.

Alpharadin is the first bone targeted therapy to show an overall survival (OS) advantage in metastatic castration-resistant prostate cancer (mCRPC). To date, none of the other therapies targeting bone in prostate cancer such as zoledronic acid (Zometa), denosumab (Xgeva) or cabozantinib (XL184) have shown any overall survival benefit.

This is a preview of Alpharadin Prostate Cancer data will be “Practice Changing” #EMCC2011. Read the full post

1 Comment

Alpharadin on fast track to FDA prostate cancer approval in 2012

By on August 25, 2011

Algeta Alpharadin 223 147x300 Alpharadin on fast track to FDA prostate cancer approval in 2012

Earlier this week Bayer & Algeta announced that Alpharadin™ (radium-223 chloride) had received Fast Track designation from the FDA for the treatment of castration-resistant prostate cancer (CRPC).

Bayer signed an agreement with Norwegian based Algeta in 2009 for the global commercial rights to Alpharadin™, with Algeta retaining a 50/50 co-promotion and profit-sharing in the United States.

According to the Algeta August 23, 2011 press release, in light of the FDA fast track designation they plan on filing for United States approval in mid-2012, ahead of previous expectations.

This is a preview of Alpharadin on fast track to FDA prostate cancer approval in 2012. Read the full post

Leave a comment

Prostate Cancer Market to expand from $1B to $5B by 2015

By on June 2, 2011

Launch of Zytiga at AUA 2011 300x225 Prostate Cancer Market to expand from $1B to $5B by 2015The market for prostate cancer therapies is set to expand from $1 billion currently to $5 billion by 2015, according to analysts reported by this morning’s Washington Post/Bloomberg news.  This is perhaps no surprise given the recent approval of abiraterone acetate (Zytiga®) from Ortho Biotech (JNJ).

New clinical data on prostate cancer clinical trial results is expected at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this weekend from many of the prostate cancer therapies in development such as MDV3100, TAK700, ARN-509, cabozantinib (XL184), ipilimumab, custirsen (OGX-11), BPX-101, alpharadin, denosumab (Xgeva®) and Prostvac-VF.

This is a preview of Prostate Cancer Market to expand from $1B to $5B by 2015. Read the full post

Leave a comment

AUA 2011 New Prostate Cancer products in development beyond the androgen axis

By on May 16, 2011

AUA 2011 Washington DC © Pieter Droppert 300x225 AUA 2011 New Prostate Cancer products in development beyond the androgen axisThere is a lot of focus at the annual meeting of the American Urological Association (AUA) here in Washington DC on metastatic castrate resistant Prostate Cancer (mCRPC), and the recently FDA approved adrenal steroid inhibitor, abiraterone acetate (Zytiga®).

Drugs in development that target the androgen receptor, such as MDV3100, are also generating a lot of interest from urologists.

However, Oliver Sartor (Tulane) in the Saturday morning satellite symposia that I attended, focused on emerging therapies in CRPC, beyond the androgen axis. His hypothesis:

“Cancers are devious and some of the mechanisms of AR activation appear to be ligand-independent and resistant to all current androgen-axis targeted therapies.”

This is a preview of AUA 2011 New Prostate Cancer products in development beyond the androgen axis. Read the full post

1 Comment

American Urological Association Annual Meeting 2011 Satellite Symposia

By on May 12, 2011

American Urological Association Banner American Urological Association Annual Meeting 2011 Satellite SymposiaI am off to Washington DC tomorrow for the annual meeting of the American Urological Association (AUA).

If you are not able to attend, then you can follow the Twitter coverage on Pharma Strategy Blog where Sally Church (@MaverickNY) will be aggregating the tweets.  The conference hashtag is #AUA2011.  I also expect to be live-tweeting from the conference.

follow me b American Urological Association Annual Meeting 2011 Satellite Symposia

Like many medical conferences in the United States, the AUA meeting kicks off with independent continuing medical education (CME) satellite symposia on topics of interest.

This is a preview of American Urological Association Annual Meeting 2011 Satellite Symposia. Read the full post

Leave a comment